Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 5:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 33,591 matching trials from the live ClinicalTrials.gov search.
Conditions
Malaria
Interventions
RTS,S/AS01E, RTS,S/AS01B, Sporozoite-infected mosquitoes challenge.
Biological · Procedure
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Silver Spring, Maryland
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism, Chronic Renal Insufficiency, Chronic Renal Failure
Interventions
CTA018 Injection
Drug
Lead sponsor
OPKO IP Holdings II, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Pembroke Pines, Florida • Meridian, Idaho • Springfield, Massachusetts + 2 more
Conditions
DLBCL, Neurotoxicity Syndromes
Interventions
Defibrotide
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Phoenix, Arizona • Baltimore, Maryland • Boston, Massachusetts + 1 more
Conditions
Conditions Requiring Diagnostic Evaluation
Interventions
Perform MRI in patients with pacemaker or ICD
Diagnostic Test
Lead sponsor
Johns Hopkins University
Other
Eligibility
9 Years to 100 Years
Enrollment
1,275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 3 Interventional Results available

Tiotropium Bromide in Cystic Fibrosis

NCT01179347
Conditions
Cystic Fibrosis
Interventions
tiotropium Respimat® inhaler, Placebo Respimat® inhaler
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
Not listed
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
15
States / cities
Tuscon, Arizona • San Diego, California • Jacksonville, Florida + 10 more
Conditions
Geographic Atrophy
Interventions
OCU410
Genetic
Lead sponsor
Ocugen
Industry
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
12
States / cities
Phoenix, Arizona • Coral Springs, Florida • Carmel, Indiana + 9 more
Conditions
Traumatic Brain Hemorrhage
Interventions
Handheld brain hematoma detector
Diagnostic Test
Lead sponsor
InfraScan, Inc.
Industry
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Monomethyl Fumarate
Drug
Lead sponsor
Banner Life Sciences LLC
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
9
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 5 more
Conditions
Multiple Sclerosis
Interventions
Interferon beta-1a, Fingolimod, Placebo capsule, Placebo i.m. injection
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
10 Years to 17 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 7 more
Conditions
Depressive Disorder, Major
Interventions
saredutant (SR48968), paroxetine, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
825 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Proteinuric Kidney Disease
Interventions
MZE829
Drug
Lead sponsor
Maze Therapeutics
Industry
Eligibility
18 Years to 68 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
68
States / cities
Decatur, Alabama • Huntsville, Alabama • Montgomery, Alabama + 56 more
Conditions
Atopic Dermatitis
Interventions
Abrocitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
0 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver
Interventions
MGL-3196
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
3
States / cities
Orlando, Florida • Saint Paul, Minnesota • San Antonio, Texas
Completed Phase 3 Interventional Results available

Safety Study of Tivanisiran to Treat Dry Eye

NCT05310422
Conditions
Dry Eye Disease
Interventions
Tivanisiran sodium ophthalmic solution, Vehicle ophthalmic solution
Drug
Lead sponsor
Sylentis, S.A.
Industry
Eligibility
18 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
25
States / cities
Chandler, Arizona • Phoenix, Arizona • Glendale, California + 21 more
Conditions
Breast Cancer
Interventions
MKC-1
Drug
Lead sponsor
CASI pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Cognitive Impairment Associated With Schizophrenia (CIAS), Cognitive Impairment, Schizophrenia
Interventions
RL-007 (Inidascamine), Placebo
Drug
Lead sponsor
Recognify Life Sciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
20
States / cities
Culver City, California • Garden Grove, California • Lafayette, California + 17 more
Conditions
Dry Eye
Interventions
OTX-DED
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
15
States / cities
Inglewood, California • Mission Hills, California • Newport Beach, California + 12 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A First-in-human Study of Multiple Doses of Topically Administered PF-07295324 and PF-07259955

NCT05206604
Conditions
Healthy
Interventions
PF-07295324, PF-07259955
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Short Bowel Syndrome, Malabsorption
Interventions
Relizorb
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 18 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Los Angeles, California • Boston, Massachusetts
Conditions
Constipation
Interventions
Vibrating Capsule
Device
Lead sponsor
Vibrant Ltd.
Industry
Eligibility
22 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Guntersville, Alabama • Jacksonville, Florida • Miami, Florida + 1 more
Conditions
B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocyctic Leukemia, Richter's Transformation
Interventions
PCI-32765, ofatumumab
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Uveitis
Interventions
Placebo, Dose 1 gevokizumab, Dose 2 gevokizumab
Drug
Lead sponsor
XOMA (US) LLC
Industry
Eligibility
18 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
51
States / cities
Chandler, Arizona • Phoenix, Arizona • Beverly Hills, California + 48 more
Conditions
Congenital Fibrinogen Deficiency
Interventions
Octafibrin
Drug
Lead sponsor
Octapharma
Industry
Eligibility
12 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Miami, Florida
Conditions
Contraception
Interventions
DR-1011
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
2,235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
55
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 46 more